Table 7.
Assessment of repeatability
| Parameter | n | Mean of Difference* | SD of Difference* | Limits of Agreement* | 95% CI† | IntraSubject SD† | InterSubject SD† |
|---|---|---|---|---|---|---|---|
| D3-creatine | |||||||
| Method 1(urine) | 14 | 1.08 | 3.15 | –5.23 to 7.38 | –0.75, 2.90 | 2.231 | 6.078 |
| Method 2 (urine) | 14 | 0.78 | 3.03 | –5.28 to 6.84 | –0.97, 2.53 | 2.143 | 5.950 |
| Method 3 (urine) | 14 | 0.30 | 3.54 | –6.78 to 7.37 | –1.74, 2.34 | 2.501 | 6.027 |
| Method 4 (plasma) | 6 | –0.14 | 3.39 | –6.92 to 6.63 | –3.70, 3.41 | 2.396 | 6.666 |
| MRI | 14 | –0.45 | 0.77 | –1.99 to 1.10 | –0.92, 0.02 | 0.546 | 6.891 |
| DXA | |||||||
| Total LBM | 14 | –0.32 | 1.06 | –2.44 to 1.80 | –0.93, 0.29 | 0.749 | 10.059 |
| ALM | 14 | –0.11 | 0.60 | –1.31 to 1.09 | –0.46, 0.24 | 0.425 | 5.268 |
| 24-h UCrn (mean of 3 days) | 14 | 1.38 | 1.34 | –1.30 to 4.07 | 0.61, 2.16 | 0.95 | 4.906 |
CI, confidence interval.
*
Difference between first and repeat assessments.
†
Estimates from mixed-effects ANOVA models.